Compare RAIL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | TLSA |
|---|---|---|
| Founded | 1901 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.1M | 206.8M |
| IPO Year | N/A | 2000 |
| Metric | RAIL | TLSA |
|---|---|---|
| Price | $8.40 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 156.3K | ★ 236.7K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $513,120,000.00 | N/A |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $3.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.31 | $0.63 |
| 52 Week High | $13.64 | $2.60 |
| Indicator | RAIL | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 44.27 |
| Support Level | $7.27 | $1.66 |
| Resistance Level | $7.94 | $1.90 |
| Average True Range (ATR) | 0.34 | 0.15 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 78.47 | 51.35 |
FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. The company has two segments: The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and rebuilds, while the Aftermarket segment includes the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The company's revenue is predominantly derived from its Manufacturing segment.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.